Clinical trial · Interventional
Utility of ICG in Benign Bone Tumors
A Single-center Study Investigating the Utility of Indocyanine Green (ICG) Fluorescence Imaging in Patients With Benign Bone Tumors Requiring Intralesional Operative Management
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with a biopsy-proven benign bone tumor for which standard of care is intralesional operative management will receive a weight-appropriate IV dose of indocyanine green (ICG, FDA-approved) the day prior to surgery during their standard pre-operative clinic visit. On the day of surgery, fluorescence images will be obtained using a non-invasive fluorescence camera.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Tumor | Bone Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Indocyanine Green | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Benign Bone patients
- description
- Patients with Benign Bone tumors requiring intralesional operative management will be administered immunofluorescent indocyanine green 24 hours prior to surgery, imaging of perfused tissues will be performed at the time of tumor removal.
- interventionNames
- Drug: Indocyanine Green
Primary outcomes (1)
- measure
- Fluorescent intensity contrast
- timeFrame
- 24 hours post injection
- description
- fluorescence contrast suitable to facilitate fluorescence-guided surgical resection of benign bone tumors (tumor-to-background ratio \> 2.0)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subjects 12 years of age or older 2. Diagnosis of any of the following that has been identified by imaging and/or biopsy: 1. Enchondroma 2. Periosteal chondroma 3. Osteochondroma 4. Chondroblastoma 5. Giant cell tumor of bone 6. Aneurysmal bone cyst 7. Unicameral (aka Simple) bone cyst 8. Chondromyxoid fibroma 9. Osteoblastoma 10. Desmoplastic fibroma 11. Fibrous dysplasia 12. Osteofibrous dysplasia 3. Intralesional operative management for their tumor planned 4. Written informed consent signed by the subject if 18 years of age or older or by parent(s) or legally authorized representative if younger than 18 years of age. If younger than 18 years of age, the child must be able to be assent. Exclusion Criteria: 1. Iodine allergy 2. Women who are pregnant or breastfeeding 3. Incarcerated individuals
References
Publications (0)
Data not yet available